This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ross, B. D. Articles by Chenevert, T. L. Search for Related Content PubMed PubMed Citation Articles by Ross, B. D. Articles by Chenevert, T. L. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers Clinical Research: Imaging, Diagnosis, and Prognosis

Minireview

Evaluation of Cancer Therapy Using Diffusion Magnetic Resonance Imaging¹

University of Michigan Medical School, Ann Arbor, Michigan 48109-0648

² To whom requests for reprints should be addressed, at University of Michigan School of Medicine, Department of Radiology, Center for Molecular Imaging, 1500 East Medical Center Drive, University Hospital, Room B2B311, Ann Arbor, MI 48109-0030. Phone: (734) 936-8866; Fax: (734) 764-2412; E-mail: tlchenev{at}umich.edu

Assessment of the effectiveness of cancer therapy traditionally relies on comparison of tumor images acquired before and after therapeutic intervention by inspection of gross anatomical images to evaluate changes in tumor size. The potential for imaging to provide additional insights related to the therapeutic impact would be enhanced if a specific parameter or combination of parameters could be identified that reflect tissue changes at the cellular or physiological level. This information could also provide a more sensitive and earlier indicator of treatment response in an individual animal or patient. Diffusion magnetic resonance imaging can detect relatively small changes in tissue structure at the cellular level and thus provides an opportunity to quantitatively and serially follow therapeutic-induced changes in solid tumors. This article provides an overview of the use of diffusion magnetic resonance imaging as a surrogate marker for quantitating treatment responsiveness in both preclinical and clinical studies.

This article has been cited by other articles:

				D. Le Bihan Intravoxel Incoherent Motion Perfusion MR Imaging: A Wake-Up Call Radiology, December 1, 2008; 249(3): 748 - 752. [Full Text] [PDF]

				D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, et al. Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival J. Clin. Oncol., July 10, 2008; 26(20): 3387 - 3394. [Abstract] [Full Text] [PDF]

				C. Catana, D. Procissi, Y. Wu, M. S. Judenhofer, J. Qi, B. J. Pichler, R. E. Jacobs, and S. R. Cherry Simultaneous in vivo positron emission tomography and magnetic resonance imaging PNAS, March 11, 2008; 105(10): 3705 - 3710. [Abstract] [Full Text] [PDF]

				P. McConville, D. Hambardzumyan, J. B. Moody, W. R. Leopold, A. R. Kreger, M. J. Woolliscroft, A. Rehemtulla, B. D. Ross, and E. C. Holland Magnetic Resonance Imaging Determination of Tumor Grade and Early Response to Temozolomide in a Genetically Engineered Mouse Model of Glioma Clin. Cancer Res., May 15, 2007; 13(10): 2897 - 2904. [Abstract] [Full Text] [PDF]

				M. I. Kettunen, A. Sierra, M. J. Narvainen, P. K. Valonen, S. Yla-Herttuala, R. A. Kauppinen, and O. H. J. Grohn Low Spin-Lock Field T1 Relaxation in the Rotating Frame as a Sensitive MR Imaging Marker for Gene Therapy Treatment Response in Rat Glioma Radiology, March 1, 2007; 243(3): 796 - 803. [Abstract] [Full Text] [PDF]

				B. A. Moffat, T. L. Chenevert, T. S. Lawrence, C. R. Meyer, T. D. Johnson, Q. Dong, C. Tsien, S. Mukherji, D. J. Quint, S. S. Gebarski, et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response PNAS, April 12, 2005; 102(15): 5524 - 5529. [Abstract] [Full Text] [PDF]

				E. Floyd and T. M. Mcshane Development and Use of Biomarkers in Oncology Drug Development Toxicol Pathol, January 1, 2004; 32(1_suppl): 106 - 115. [Abstract] [PDF]